HR 3348
115th Congress
House
Health
Cardiovascular and respiratory health
Drug safety, medical device, and laboratory regulation
Drug therapy
Infectious and parasitic diseases
Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act
Introduced: July 20, 2017
Introduced by:
Peters, Scott H.
Democratic
· California
See on congress.gov
Everywhere this bill has been
2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 20, 2017
Referred to the House Committee on Energy and Commerce.
Jul 20, 2017
Introduced in House
Plain-English summary
Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act
This bill amends the Federal Food, Drug, and Cosmetic Act to include Middle East respiratory syndrome under the priority review voucher program for tropical diseases, which awards a voucher to the sponsor of a new drug or biological product that is approved to prevent or treat a tropical disease. (A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.)
What's happening now
Referred to the House Committee on Energy and Commerce.
Committees of jurisdiction
1